Telegram
Protagonist Therapeutics PTGX
$ 26.09
2.15%
Facebook
Twitter
ВКонтакте
Telegram
Сообщить о неточностиProtagonist Therapeutics Мультипликаторы 2011-2024 | PTGX
Мультипликаторы по годам Protagonist Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-21.3 | -9.3 | -10.8 | -10.8 | -2.5 | -4.6 | -10.5 | -3.3 | - | - | - | - | - |
P/S |
28.0 | 44.5 | 49.6 | 24.9 | 822.8 | 5.9 | 19.4 | - | - | - | - | - | - |
EPS |
-1.4 | -2.6 | -2.7 | -1.9 | -3.0 | -1.7 | -2.1 | -5.8 | -59.3 | -49.4 | - | - | - |
EV (Enterprise Value) |
1.52 млрд | 1.09 млрд | 1.28 млрд | 640 млн | 232 млн | 126 млн | 326 млн | 108 млн | 1.19 млн | 2.37 млн | - | - | - |
EBITDA per Share |
-1.63 | -2.66 | -2.7 | -1.85 | -3.01 | -1.87 | -2.12 | -4.98 | - | - | - | - | - |
EV/EBITDA |
-10.1 | -10.7 | -2.1 | -2.4 | -7.5 | -3.1 | - | - | - | - | - | ||
PEG |
-3.73 | -0.84 | 100.33 | -0.33 | 0.03 | -0.28 | -0.16 | 0.05 | - | - | - | - | - |
P/B |
5.0 | 5.5 | 4.5 | 2.5 | 2.4 | 1.6 | 3.2 | 1.4 | - | - | - | - | - |
P/CF |
-23.9 | -10.9 | -12.6 | -9.8 | -4.5 | -3.6 | 121.2 | -4.0 | - | - | - | - | - |
ROE % |
-23.45 | -59.09 | -41.85 | -23.66 | -96.53 | -34.59 | -30.64 | -42.46 | - | - | - | - | - |
ROA % |
-22.06 | -51.38 | -36.11 | -20.39 | -49.82 | -27.91 | -22.57 | -39.55 | - | - | - | - | - |
ROCE % |
-27.82 | -60.93 | -41.95 | -23.07 | -67.38 | -37.30 | -31.27 | -37.31 | - | - | - | - | - |
Current Ratio |
16.8 | 7.7 | 7.3 | 7.2 | 4.1 | 5.3 | 3.5 | 12.9 | - | - | - | - | - |
DSO |
- | - | - | - | 10673.5 | 71.0 | 57.5 | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Операционный цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Финансовый цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Все данные представлены в валюте USD
Мультипликаторы поквартально Protagonist Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.58 | -0.68 | -0.67 | - | -0.64 | -0.84 | -0.43 | - | -0.7 | -0.69 | -0.54 | - | -0.21 | -0.59 | -0.72 | -0.63 | -0.61 | -1.18 | -0.58 | -0.57 | -0.38 | -0.41 | -0.36 | -0.15 | -0.29 | -0.89 | -0.84 | -0.67 | -0.87 | -19.07 | -40.96 | -20.31 | -12.79 | -13.78 | -11.75 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | -0.71 | - | -0.64 | -0.84 | -0.43 | - | -0.69 | -0.69 | -0.54 | - | -0.19 | -0.54 | -0.7 | -0.64 | -0.62 | -1.26 | -0.6 | -0.66 | -0.39 | -0.42 | -0.39 | -0.17 | -0.28 | -0.89 | -0.85 | -0.68 | -0.81 | -18.1 | -24.2 | -18.4 | -14.2 | -12.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-52.79 | -54.32 | -56.56 | -35.07 | -45.32 | -42.76 | -36.07 | -28.14 | -30.91 | -23.43 | -21.75 | -16.90 | -38.79 | -56.53 | -86.07 | -96.53 | -86.96 | -74.21 | -45.42 | -34.59 | -24.80 | -21.04 | -25.76 | -30.64 | -40.95 | -45.04 | -40.73 | -42.46 | -9.57 | 11.11 | 30.97 | 44.38 | 24.34 | 11.75 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-47.46 | -48.20 | -42.21 | -23.09 | -32.15 | -24.13 | -31.76 | -24.74 | -27.13 | -20.47 | -18.82 | -14.57 | -25.86 | -34.06 | -46.91 | -49.82 | -48.47 | -44.14 | -31.52 | -27.91 | -19.83 | -16.51 | -19.45 | -22.57 | -32.67 | -37.26 | -35.67 | -39.55 | -64.59 | -80.29 | -94.42 | -81.92 | -44.92 | -21.68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-57.01 | -57.59 | -58.65 | -35.72 | -46.01 | -43.04 | -36.22 | -28.19 | -30.97 | -23.46 | -21.34 | -16.34 | -37.97 | -56.66 | -89.42 | -100.70 | -92.76 | -79.64 | -48.57 | -37.57 | -26.78 | -22.57 | -26.90 | -31.42 | -41.52 | -45.54 | -41.10 | -37.31 | -6.04 | 16.79 | 36.14 | 44.18 | 25.93 | 11.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
11.8 | 12.1 | 10.1 | 7.7 | 7.3 | - | 7.5 | 7.3 | 8.6 | 8.6 | 7.7 | 7.2 | 7.2 | 7.2 | 7.2 | 2.1 | 2.1 | 2.1 | 2.1 | 5.2 | 5.2 | 5.2 | 5.2 | 3.8 | 3.8 | 3.8 | 3.8 | 14.6 | 14.6 | 14.6 | - | 2.8 | 2.8 | 2.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Операционный цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Финансовый цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Все данные представлены в валюте USD